Publications by authors named "J Waltenberger"
In contrast to the extensive evidence from animal studies, only few human data are available on the relation of vascular growth factors and collateral function as well as on the conditions which may modify their release or function. In 31 patients with total coronary occlusion (TCOs) blood was collected from distal to the occlusion site (collateral circulation) and from the aortic root (systemic circulation). Serum was used to assess its mitogenic potential in [H]-thymidine incorporation assay on human umbilical vein endothelial cells.
View Article and Find Full Text PDFArticle Synopsis
- Non-vitamin-K oral anticoagulants like Edoxaban are effective for preventing strokes in patients with atrial fibrillation (AF), but there's limited data on their long-term outcomes in routine care in Germany, Austria, and Switzerland (DACH).
- The ETNA-AF-Europe study enrolled 13,092 AF patients across 10 European countries, with 5,457 patients from the DACH region, revealing that the majority received appropriate Edoxaban dosing.
- After one year, the study found low rates of stroke (0.8%/year) and severe bleeding (0.7%/year), but higher age and frailty were linked to increased mortality and complications.
Background: To assess long-term effectiveness and safety of edoxaban in Europe.
Methods And Results: ETNA-AF-Europe, a prospective, multinational, multi-centre, post-authorisation, observational study was conducted in agreement with the European Medicines Agency. The primary and secondary objectives assessed real-world safety (including bleeding and deaths) and effectiveness (including stroke, systemic embolic events and clinical edoxaban use), respectively.
Valvular heart disease (VHD) is common and poses important challenges from the standpoints of diagnosis and therapeutic management. Clinical practice guidelines have been developed to help health care professionals to overcome these challenges and provide optimal management to patients with VHD. The American College of Cardiology, in collaboration with the American Heart Association, and the European Society of Cardiology, in collaboration with the European Association for Cardio-Thoracic Surgery, recently updated their guidelines on the management of VHD.
View Article and Find Full Text PDFPurpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-REG trial). Since SGLT-2 is known to be expressed on cells other than the kidney cells, we investigated the potential ability of empagliflozin to regulate glucose transport and alleviate hyperglycaemia-induced dysfunction of these cells.
View Article and Find Full Text PDF